
Ask Dr. Shilpa: Why clinical studies on supplements are challenging to design and why outcomes differ

In a wellness landscape where clinical studies are often treated as the gold standard, the reality is far more nuanced, especially when it comes to supplements. In this edition of Ask Dr. Shilpa, we sit down with Dr. Shilpa Raut, Vice President of Research and Development at Cymbiotika, to unpack why supplement research can feel so inconsistent and what most people are getting wrong when they read headlines.
From the challenges of designing clinical trials for nutrients to the overlooked role of dosage, bioavailability, and delivery systems, this conversation pulls back the curtain on why some studies show little to no benefit and what that actually means for real-world use. She also gets into the difference between testing single ingredients versus finished formulas, and how to more intelligently evaluate whether a supplement is worth taking in the first place.
If you’ve ever wondered why “the science” around supplements feels contradictory, this is the clarity you’ve been looking for.
Clinical studies are often treated as the gold standard, but when it comes to supplements, the picture feels less clear. Why do outcomes differ?
Some large trials and meta-analyses sometimes conclude that common supplements show little or no benefit. For example, a 2021 JACC review found no clear effect for commonly used multivitamins, vitamin D, calcium, and vitamin C on cardiovascular outcomes and all-cause mortality, and noted that conclusive benefit across different dietary backgrounds has not been shown when people are already nutrient sufficient. The VITAL trial similarly found that vitamin D did not lower cardiovascular events overall, and marine omega-3s did not lower major cardiovascular events or cancer overall in a generally healthy population.
One question to ask is: Did these clinicals use products that were bioavailable? You can take the best bioactive ingredients on the planet — carotenoids, polyphenols, antioxidants, phytosterols — and still get almost none of their benefits. Not because the ingredients are wrong. Because the delivery form is broken.
Another difference to consider is that drugs are usually tested to treat or manage a disease state, while supplements are generally positioned to support normal structure or function in healthy people. From a regulatory standpoint, dietary supplements are not intended to diagnose, treat, cure, or prevent disease; those are drug claims. That changes the type of population, endpoints, and claims a supplement company can study.
With drugs, you may be studying patients who clearly have a condition and a measurable clinical endpoint. With supplements, you are often studying healthy people or people who are “not sick enough” to qualify as patients. That means the expected effect size is often smaller, takes longer to detect, and is more influenced by baseline nutrition, lifestyle, sleep, stress, genetics, microbiome, and diet. Reviews on nutraceutical trial design have pointed out that nutrients are not like drugs: they work in networks, affect many tissues, and the body’s baseline nutrient status can strongly influence response.
In a controlled study, participants are expected to follow instructions closely. In real life, that’s rarely the case. How much does consistency or user behavior impact outcomes? Do you think some supplements “fail” in studies simply because they require a level of compliance that’s hard to maintain outside a trial?











